PT  - JOURNAL ARTICLE
AU  - Pavithra Jayasundara
AU  - Kalaiarasu M. Peariasamy
AU  - Kian Boon Law
AU  - Ku Nurhasni Ku Abd Rahim
AU  - Sit Wai Lee
AU  - Izzuna Mudla M. Ghazali
AU  - Milinda Abayawardana
AU  - Linh-Vi Le
AU  - Rukun K.S.Khalaf
AU  - Karina Razali
AU  - Xuan Le
AU  - Zhuo Lin Chong
AU  - Emma S McBryde
AU  - Michael T Meehan
AU  - Jamie M. Caldwell
AU  - Romain Ragonnet
AU  - James M Trauer
TI  - Sustaining effective COVID-19 control in Malaysia through large-scale vaccination
AID  - 10.1101/2021.07.05.21259999
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.05.21259999
4099  - http://medrxiv.org/content/early/2021/07/07/2021.07.05.21259999.short
4100  - http://medrxiv.org/content/early/2021/07/07/2021.07.05.21259999.full
AB  - Introduction As of 3rd June 2021, Malaysia is experiencing a resurgence of COVID-19 cases. In response, the federal government has implemented various non-pharmaceutical interventions (NPIs) under a series of Movement Control Orders and, more recently, a vaccination campaign to regain epidemic control. In this study, we assessed the potential for the vaccination campaign to control the epidemic in Malaysia and four high-burden regions of interest, under various public health response scenarios.Methods A modified susceptible-exposed-infectious-recovered compartmental model was developed that included two sequential incubation and infectious periods, with stratification by clinical state. The model was further stratified by age and incorporated population mobility to capture NPIs and micro-distancing (behaviour changes not captured through population mobility). Emerging variants of concern (VoC) were included as an additional strain competing with the existing wild-type strain. Several scenarios that included different vaccination strategies (i.e. vaccines that reduce disease severity and/or prevent infection, vaccination coverage) and mobility restrictions were implemented.Results The national model and the regional models all fit well to notification data but underestimated ICU occupancy and deaths in recent weeks, which may be attributable to increased severity of VoC or saturation of case detection. However, the true case detection proportion showed wide credible intervals, highlighting incomplete understanding of the true epidemic size. The scenario projections suggested that under current vaccination rates complete relaxation of all NPIs would trigger a major epidemic. The results emphasise the importance of micro-distancing, maintaining mobility restrictions during vaccination roll-out and accelerating the pace of vaccination for future control. Malaysia is particularly susceptible to a major COVID-19 resurgence resulting from its limited population immunity due to the country’s historical success in maintaining control throughout much of 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the World Health Organization Regional Office for the Western Pacific and the Australian Medical Research Future Fund COVID-19 Rapid Response Digital Health Infrastructure scheme (RRDHI000027). JMT is a recipient of an Early Career Fellowship from the Australian National Health and Medical Research Council (APP1142638). MTM is a recipient of a Discovery Early Career Researcher Award from the Australia Research Council (DE210101344). JMS is funded by the United States National Aeronautics and Space Administration Ecological Forecasting program (NNX17AI21G).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB oversight was needed for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analysed during the current study and model code are publicly available. https://github.com/monash-emu/AuTuMN/ MCOmovement control orderICUintensive care unitNPInon-pharmaceutical interventionsVoCvariants of concern